• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Prelude Therapeutics Incorporated - Common Stock (NQ:PRLD)

    4.640 +0.750 (+19.28%)
    Streaming Delayed Price Updated: 11:01 AM EDT, Jul 28, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 921,980
    Open 4.550
    Bid (Size) 4.640 (200)
    Ask (Size) 4.660 (100)
    Prev. Close 3.890
    Today's Range 4.190 - 4.870
    52wk Range 0.7500 - 5.690
    Shares Outstanding 54,808,715
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Which stocks are gapping on Tuesday? ↗
    Via Chartmill
    Which stocks are moving before the opening bell on Tuesday? ↗
    Via Chartmill

    Performance

    YTD
    +70.0%
    +70.0%
    1 Month
    -5.9%
    -5.9%
    3 Month
    +2.7%
    +2.7%
    6 Month
    +128.6%
    +128.6%
    1 Year
    +444.5%
    +444.5%

    More News

    Read More
    News headline image
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
    Via Benzinga
    Prelude Therapeutics (NASDAQ:PRLD) Reports Narrower Quarterly Loss, Shares Rise on Cash Runway Extension ↗
    Via Chartmill
    News headline image
    Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    News headline image
    Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    News headline image
    Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    News headline image
    Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    News headline image
    Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    News headline image
    Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    News headline image
    The $71 Billion Cancer Shift: Why The FDA Is Speeding Up
    From Equity Insider
    Via GlobeNewswire
    News headline image
    Why Did PRLD Stock Surge 13% Today? ↗
    Via Stocktwits
    News headline image
    Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    News headline image
    Cancer Drug Developers Secure Regulatory Clarity as FDA Reshapes Approval Standards
    From Equity Insider
    Via GlobeNewswire
    News headline image
    Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    News headline image
    PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
    Via FinancialNewsMedia
    News headline image
    Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B
    From FN Media Group LLC
    Via GlobeNewswire
    News headline image
    12 Health Care Stocks Moving In Thursday's After-Market Session ↗
    Via Benzinga
    News headline image
    Prelude Therapeutics Inc. (NASDAQ:PRLD) Beats Q3 2025 Earnings Estimates and Extends Cash Runway ↗
    Via Chartmill
    News headline image
    Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
    From Prelude Therapeutics, Incorporated
    Via GlobeNewswire
    News headline image
    PRLD Investors Have Opportunity to Join Prelude Therapeutics Incorporated Fraud Investigation With the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    News headline image
    In today's session, these stocks are experiencing unusual volume. ↗
    Via Chartmill
    News headline image
    12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
    Via Benzinga

    Frequently Asked Questions

    Is Prelude Therapeutics Incorporated - Common Stock publicly traded?
    Yes, Prelude Therapeutics Incorporated - Common Stock is publicly traded.
    What exchange does Prelude Therapeutics Incorporated - Common Stock trade on?
    Prelude Therapeutics Incorporated - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Prelude Therapeutics Incorporated - Common Stock?
    The ticker symbol for Prelude Therapeutics Incorporated - Common Stock is PRLD on the Nasdaq Stock Market
    What is the current price of Prelude Therapeutics Incorporated - Common Stock?
    The current price of Prelude Therapeutics Incorporated - Common Stock is 4.640
    When was Prelude Therapeutics Incorporated - Common Stock last traded?
    The last trade of Prelude Therapeutics Incorporated - Common Stock was at 07/28/26 11:01 AM ET
    What is the market capitalization of Prelude Therapeutics Incorporated - Common Stock?
    The market capitalization of Prelude Therapeutics Incorporated - Common Stock is 254.31M
    How many shares of Prelude Therapeutics Incorporated - Common Stock are outstanding?
    Prelude Therapeutics Incorporated - Common Stock has 254M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.